Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered subcutaneously as compared to placebo in patients with atherosclerotic cardiovascular disease and elevated Lipoprotein(a).
In results revealed at AHA 2022, the trial showed that when dosed at 75mg or higher every 12 weeks, olpasiran reduced Lp(a) concentration by more than 95% in patients with atherosclerotic cardiovascular disease, and the treatment to be safe and well-tolerated.
This trial update from ESC 2023 investigated an off-treatment period in the same patient group. This late-breaking update revealed that patients treated with a higher dose of olpasiran had a 40-50% reduction in LP(a) up to a year after their last dose.
Questions:
-What do we know about the role of Lp(a)? What are the available treatments for addressing Lp(a) concentrations?
-What question does this extension study aim to address?
-What was the study design and eligibility criteria?
-What are the key findings presented at ESC?
-What are the take-home messages?
-What are the remaining questions? What are the next steps?
Recorded on-site at ESC Congress 2023, Amsterdam.
Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on Twitter: / radcliffecardio